Introduction
The transforming growth factor b (TGFb) superfamily is composed of homodimeric polypeptide growth factors, including TGFb isoforms, bone morphogenetic proteins, growth and differentiation factors, activins and inhibins. The TGFb signaling pathway has essential roles in regulating many cellular responses including proliferation, differentiation, migration and apoptosis (1) (2) (3) (4) (5) . There are three TGFb isoforms, TGFb1, TGFb2 and TGFb3, which are encoded by distinct genes and expressed in both a tissue-specific and a developmentally regulated manner. TGFb exerts its biological function through binding to three high-affinity cell-surface receptors, the TGFb type I, type II and type III receptors (TbRI or ALK-5, TbRII and TbRIII or betaglycan, respectively). TbRI and TbRII contain serine/threonine protein kinases in their cytoplasmic domains. Upon ligand binding, TbRII recruits and phosphorylates TbRI, activating its kinase activity to initiate intracellular signaling. TbRI signals by directly phosphorylating Smad2 and Smad3, which form a complex with the common mediator Smad4, translocate to nucleus and regulate gene transcription (6, 7) . While Smad-dependent pathways represent a major mechanism for TGFb signaling, crosstalk and signaling through Smad-independent pathways, including the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/Akt pathways has been reported (8) (9) (10) (11) (12) (13) (14) . However, the mechanism by which TGFb activates Smad-independent pathways including MAPK pathways remains unclear.
TbRIII is the most abundant TGFb receptor and is traditionally thought to function as a co-receptor, binding TGFb and presenting it to TbRII (15) . This is particularly important for the TGFb2 isoform, which cannot bind TbRII independently. In addition, several studies support essential, non-redundant roles for TbRIII in mediating TGFb sensitivity in intestinal goblet cells (16) in the mesenchymal transformation of chick embryonic heart development (17) and for mouse embryonic development (18) . We recently reported the frequent loss of TbRIII expression in human breast (19) , prostate (20) and ovarian cancers (21) , with loss of expression correlating with disease progression and re-expression studies establishing a direct role for TbRIII in regulating cancer cell migration and invasion in vitro and angiogenesis and metastasis in vivo.
TbRIII has a short cytoplasmic domain without kinase activity. While this cytoplasmic domain is not essential for mediating the presentation role, it does contribute to TbRIII/TGFb-mediated inhibition of proliferation (22) . We also established specific functions of the cytoplasmic domain including mediating interaction with GAIPinteracting protein, C-terminus (GIPC), a PDZ domain-containing protein, to stabilize TbRIII on the cell surface and enhance TGFb signaling (22) , and phosphorylation by TbRII, which serves to recruit the scaffolding protein b-arrestin2, mediate the co-internalization of TbRII and TbRIII and down-regulate TGFb signaling (23) . Here, we explore the mechanism by which TbRIII enhances TGFb-mediated inhibition of proliferation.
Materials and methods

Materials and plasmids
Dulbecco's modified Eagle's medium was purchased from Invitrogen Co. (Carlsbad, CA), and defined fetal bovine serum was from Hyclone (Logan, UT). Fugene 6 was from Roche Molecular Biochemicals and SB203580, LY294002, SP600125 and PD98059 were purchased from Calbiochem (La Jolla, CA). SB431542 was from Sigma (St Louis, MO). TGFb1 and TGFb2 were from R&D systems (Minneapolis, MN). G418 was from Calbiochem. Mouse monoclonal antibody specific for Smad2, rabbit polyclonal antibodies specific for phospho-Smad2, phosphor-Smad3, p38, phosphor-p38 and horseradish peroxidase-conjugated anti-mouse and anti-rabbit antibodies were from Cell Signaling Technology (Beverly, MA) and rabbit polyclonal antibody against Smad3 was from Calbiochem. Alexa488-conjugated anti-mouse or Cy TM 3-conjugated anti-rabbit secondary antibodies were from Jackson ImmunoResearch Laboratories (West Grove, PA). pcDNA3-Flag-p38a (AF) was generously provided by Dr Han at Scripps Institute (CA).
Cell culture and adenoviral infection
Rat L6 myoblasts (CRL-2256) and HaCaT cells were obtained from the American Type Culture Collection. L6 myoblasts and HaCaT cells were maintained as monolayers in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal bovine serum. L6-Neo, L6-TbRIII and L6-TbRIII-Cyto stable cell lines were selected in 0.6 mg/ml G418 and maintained in growth media containing 0.3 mg/ml G418 as described previously (23, 24) . Normal human mammary epithelial cell (HMEC) strains 1001-15 and 1001-16 were purchased from Clonetics (San Diego, CA). HMECs were grown in mammary epithelial cell basal medium (Clonetics) supplemented with 4 lg/ml bovine pituitary extract, 5 lg/ml insulin (Sigma), 20 ng/ml epidermal growth factor (UBI, Lake Placid, NY) and 0.5 lg/ml hydrocortisone (Sigma) as described previously (25) . Normal ovarian surface epithelial (NOSE) cells were generously provided by Dr Andrew Berchuck and grown in RPMI1640 supplemented with 10% fetal bovine serum. Adenoviral infection of short hairpin RNA (shRNA) of TbRIII was performed by plating cells, adding virus as indicated and incubating for 2 days for experiments. All cells were grown in 5% CO 2 at 37°C in a humidified atmosphere. Radioligand binding and cross-linking of   125 I-TGFb1 to TGFb receptors in each cell lines were performed by incubating subconfluent cells with KRH buffer [50 mM N-2-hydroxyethylpiperazine-N#-2-ethanesulfonic acid (HEPES), pH 7.5, 130 mM NaCl, 5 mM MgSO 4 , 1 mM CaCl 2 and 5 mM KCl] containing 0.5% bovine serum albumin for 30 min at 37°C, and then with 100 pM 125 I-TGFb1 for 3 h at 4°C.
Binding and cross-linking assay
125
I-TGFb1 was cross-linked with 0.5 mg/ml disuccinimidyl suberate and quenched with 20 mM glycine. Cells were then washed with KRH buffer, lysed in RIPA buffer, immunoprecipitated with the indicated antibodies and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and phosphorimaging analysis of dried gels.
Transcription reporter luciferase assay Cells (3 Â 10 4 ) were grown in a 24-well plate and transfected with a p3TP vector containing the luciferase gene under the regulation of a promoter based on the TGFb-inducible promoter (a part of the PAI-1 promoter), pE2.1 vector containing the luciferase gene under 36 bp-pE2.1 element of PAI-1 gene (6, 26, 27) or pARE-FAST-1 (13) and the pRL-SV40 vector (Promega) expressing Renillar luciferase under the control of SV40 promoter to control for transfection efficiency using Fugene 6. Besides those reporter plasmids, some cells were transfected with pcDNA3, pcDNA3-Flag-p38a (WT), pcDNA3-Flag-p38a (AF) (28), pcDNA3-Flag-Smad3 or pcDNA3-Flag-Smad3DE (29) . After 24 h, the cells were incubated with or without TGFb1 (100 pM) or TGFb2 (200 pM) for 20 h before harvest. Luciferase activities were measured in a multi-label counter (PerkinElmer) using the dual-luciferase reporter assay system (Promega). 
Immunofluorescence
To localize Smads, cells were plated on coverslips and grown for 48 h. Then, cells were treated with TGFb1 for 40 min. The reaction was stopped with cold phosphate-buffered saline. The cells were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100 and blocked with 5% bovine serum albumin/phosphate-buffered saline, followed by incubation with anti-Smad2 or anti-Smad3 antibodies (1:200) at room temperature for 2 h. Thereafter, they were washed, incubated with Alexa488-conjugated anti-mouse or Cy 
Subcellular fractionation
To assess the localization of Smads, protein extract was prepared as followed (30) . Cells (5 Â 10 5 ) were grown in a 60 mm dish for 48 h and treated with TGFb (100 pM) for 40 min. Then, the cells were washed with phosphatebuffered saline and re-suspended in eight packed cell volumes of hypotonic buffer (10 mM HEPES, pH 7.9, 1.5 mM MgCl 2 , 10 mM KCl, 0.2 mM phenylmethylsulfonylfluoride and 0.5 mM dithiothreitol). Cells were allowed to swell for 10 min on and transferred to a Dounce homogenizer for processing with a type B pestle. Nuclei were collected from ruptured cells by centrifugation for 15 min at 4000 r.p.m. and suspended in one-half packed pellet volume of cold, low-salt buffer (20 mM HEPES, pH 7.9, 25% glycerol, 1.5 mM MgCl 2 , 0.02 M KCl, 0.2 mM ethylenediaminetetraacetic acid, 0.2 mM phenylmethylsulfonylfluoride and 0.5 mM dithiothreitol). High-salt buffer (20 mM HEPES, pH 7.9, 25% glycerol, 1.5 mM MgCl 2 , 1.2 M KCl, 0.2 mM phenylmethylsulfonylfluoride and 0.5 mM dithiothreirol) equal to one-half packed pellet volume was added, and the nuclei were further extracted with gentle rocking for 30 min at 4°C. Nuclei were collected by centrifugation for 30 min at 14 500 r.p.m., dialyzed and applied to biochemical assays.
Western blotting
Protein samples were heated to 95°C for 5 min and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis on 8 or 10% acrylamide gels, followed by transfer to polyvinylidene difluoride membranes for 1 h at 350 mA with a NOVEX semi transfer unit. Membranes were then blocked for 1 h in Tris-buffered saline with 0.01% Tween 20 with 5% non-fat dried milk, after which they were incubated for 2 h with primary antibody in Tris-buffered saline with 0.01% Tween 20 with 2% bovine serum albumin, followed by 1 h with horseradish peroxidase-conjugated anti-mouse or rabbit antibody. The blots were developed with an enhanced chemiluminescence kit (Amersham Pharmacia Biotech), and quantification of band intensity on XAR-5 film (Eastman Kodak Co.) was measured by Quantity One software (Bio-Rad, Chicago, IL).
shRNA-mediated silencing of human TbRIII in human epithelial cells TbRIII knockdown was achieved by shRNA-mediated silencing of TbRIII via adenoviral transduction. Briefly, human TbRIII small interfering RNAs were designed and purchased from Dharmacon (Lafayette, CO). A 66 bp oligonucleotide linker containing human TbRIII-specific sense and corresponding anti-sense sequences, flanking a 6 base hairpin, was generated and subcloned into pSiren-DNR-DsRed-Express, which was then utilized to prepare an adenoviral vector which expresses shRNA-targeting TbRIII (shRIII) (Clontech, Mountain View, CA). Adeno X-LP-shRIII or GFP adenovirus was produced in the Phoenix cell packaging line. For shRNA knockdown, HaCaT cells, HMECs and NOSE007 cells were infected with Adeno-X-shRIII or control GFP adenoviruses, the selective knockdown of TbRIII verified by 125 I-TGFb1 binding and cross-linking and reverse transcription-polymerase chain reaction.
Statistical analysis
All data are expressed as percentages of control and shown as means ± SDs. Statistical comparisons between groups were made using Student's t-tests. Values of P , 0.01 were considered significant.
Results
TbRIII increases TGFb1-induced growth inhibition
We previously demonstrated that TbRIII-enhanced growth inhibition in TGFb2-stimulated L6 myoblasts and that the cytoplasmic domain of TbRIII contributed to this response (22, 24) . As TGFb2 does not bind TbRII independently and thus is more dependent on TbRIII for signaling (31, 32) , to establish a broader role for TbRIII and to identify the signaling mechanism by which TbRIII mediates TGFb-induced growth inhibition, we examined TGFb1-mediated growth inhibition in the L6 myoblast model system. L6 myoblasts express no TbRIII, while expressing TbRII and TbRI, and are minimally responsive to TGFb1-mediated growth inhibition. While empty vector-transfected and selected L6-Neo cells expressed no TbRIII, TbRIII and TbRIII-Cyto (TbRIII lacking a cytoplasmic domain) expression vector-transfected and selected L6-TbRIII and L6-TbRIII-Cyto cells expressed TbRIII and TbRIII-Cyto, respectively, at comparable levels ( Figure 1A ). These stable cell lines consist of pools of individual clones, minimizing clonal variability. TGFb1 decreased [ 3 H]thymidine incorporation in L6-TbRIII cells with up to 60% inhibition at 32 h relative to untreated L6-TbRIII cells ( Figure 1B ). In contrast, TGFb1 either modestly stimulated or inhibited thymidine incorporation in L6-Neo cells by ,20% ( Figure 1B ). To investigate the role of cytoplasmic domain of TbRIII in TGFb1-mediated growth regulation, we examined TGFb1-mediated growth inhibition in L6-Neo, L6-TbRIII and L6-TbRIII-Cyto cells over a dose range of TGFb1 from 0 to 1000 pM ( Figure 1C and D) . In L6-TbRIII cells, TGFb1 induced growth inhibition beginning at 10 pM and reaching a maximum of 50% inhibition at 100 pM TGFb1. In contrast, in L6-TbRIII-Cyto cells, the effects of TGFb1 were markedly abrogated, with ,20% inhibition at 100 pM TGFb1. The significant difference in TGFb1-mediated growth inhibition between L6-TbRIII and L6-TbRIII-Cyto cells was maintained from 50 to 1000 pM of TGFb1. In addition, TbRIII restored TGFb2-induced growth inhibition, in a cytoplasmic domain-dependent manner ( Figure 1E ), consistent with our previous studies (24) . These results demonstrate that TbRIII has an important role in TGFb1 as well as TGFb2-mediated growth regulation, mediated, in part, through its cytoplasmic domain.
TbRIII enhances Smad3-dependent signaling
TbRIII is traditionally thought to increase TGFb signaling through enhancing ligand binding to TbRII, i.e. ligand presentation (15) .
However, we had previously reported and confirmed here ( Figure 1A ) that TbRIII-Cyto was indistinguishable from TbRIII in terms of TGFb1 ligand presentation to TbRII (24) . In addition, TbRIII did not shift the TGFb1 dose response relative to TbRIII-Cyto, with maximal inhibition at 100 pM TGFb1 in both cell lines ( Figure 1C and D) , suggesting that the effects of TbRIII on TGFb1-mediated inhibition of proliferation were independent of ligand presentation effects.
TGFb1 activates TbRI by forming ternary complex of TbRII with TbRI followed by transphosphorylation. Activated TbRI then phosphorylates Smad2 and Smad3, which accumulate in the nucleus with Smad4 to activate gene expression. To define the mechanism by which TbRIII enhances TGFb1-mediated growth inhibition in L6 myoblasts, we examined the activation of Smad2 and Smad3 in TGFb1-stimulated L6-Neo, L6-TbRIII and L6-TbRIII-Cyto cell lines. While TGFb1-induced Smad2 phosphorylation was modestly decreased in the L6-TbRIII and L6-TbRIII-Cyto cell lines relative to the L6-Neo cell line, TGFb1-induced Smad3 phosphorylation was consistently increased in the L6-TbRIII and L6-TbRIII-Cyto cell relative to the L6-Neo cell line (Figure 2A ).
To assess whether these differences in Smad phosphorylation were reflected by differential nuclear accumulation of Smad2 and Smad3, we examined nuclear accumulation by both immunofluorescence microscopy and cell fractionation studies. While TGFb1 induced Smad2 ( Figure 2B ) and Smad3 ( Figure 2C ) nuclear accumulation in both L6-Neo and L6-TbRIII cell lines, TbRIII expression increased both basal and TGFb1-induced nuclear localization of Smad3 ( Figure  2C ). To quantify these effects, we performed cell fractionation studies. In unstimulated L6-Neo cells, most Smad3 was located in cytoplasm and TGFb1 induced nuclear accumulation of $13% of cellular Smad3. In unstimulated L6-TbRIII and L6-TbRIII-Cyto cell lines, 8.7 and 23.7% of cellular Smad3 was localized in the nucleus under basal conditions, respectively, and this was further increased by TGFb1 treatment to 33.2 and 41.0%, respectively ( Figure 2D and E). Taken together, these results support a role for TbRIII in specifically increasing Smad3 phosphorylation and nuclear accumulation. Interestingly, as enhanced phosphorylation and nuclear accumulation of Smad3 was also observed in L6-TbRIII-Cyto cells, these studies suggest that cytoplasmic domain of TbRIII is not essential for these effects.
To further investigate the role of TbRIII in Smad3-dependent transcriptional responses, we investigated the activation of the Smad3-dependent reporter, pE2.1-luciferase (26) and a Smad3-and AP1-dependent reporter, 3TP-luciferase (7,27,33-35) in these stable cell lines. Consistent with differences in Smad3 phosphorylation and Mechanism of TbRIII-mediated growth regulation nuclear accumulation, TbRIII expression in the L6-TbRIII cells increased Smad3-dependent transcriptional responses of both the pE2.1 ( Figure 3A ) and 3TP-luciferase ( Figure 3B ) reporters, with a slightly diminished effect in the L6-TbRIII-Cyto cell line. To confirm the role of Smad3 and its activity in TbRIII-mediated enhanced transcriptional activation in response to TGFb, a dominant-negative mutant of Smad3 (Smad3DE) which cannot be phosphorylated by TbRI (29) was introduced L6-Neo, L6-TbRIII and L6-TbRIII-Cyto cells. Although expression of Smad3DE reduced 3TP induction in response to TGFb1 and TGFb2, this diminished activation was most pronounced in the L6-TbRIII-Cyto cells ( Figure 3D ), further suggesting that the cytoplasmic domain was not involved in TbRIII-mediated Smad3 signaling. To determine whether these effects were specific to Smad3, we also examined activation of the Smad2-dependent reporter, pARE with its co-activator, FAST-1 (13, 36, 37) . In L6-Neo cells, TGFb only modestly induced transcriptional activation of pARE with a maximum of 2-fold induction, and expression of TbRIII did not significantly alter TGFb1-mediated pARE transcriptional activation ( Figure 3C ). Taken together, the ability of TbRIII to specifically increase Smad3 (and not Smad2) phosphorylation, nuclear accumulation and Smad3-dependent transcriptional responses suggest that TbRIII contributes to TGFb-mediated signaling by enhancing Smad3 activation. The ability of TbRIII-Cyto to mediate these effects and for Smad3DE to potently block TbRIII-Cyto/TGFb-mediated gene induction also suggests that the effects of TbRIII on Smad3 signaling are largely independent of its cytoplasmic domain.
p38 kinase and TbRI inhibitors reverse TbRIII-mediated increases in TGFb1-induced growth inhibition Although TbRIII enhanced Smad3 activation and Smad3-dependent transcriptional responses, these differences were not enough to explain the enhanced TGFb1-induced inhibition in L6-TbRIII. Furthermore, TbRIII-Cyto was also effective in Smad3 activation and Smad3-dependent transcriptional responses, while not able to mediate the effects of TbRIII on inhibition of proliferation. These observations suggested that Smad3-dependent signaling may not be wholly responsible for the effects of TbRIII on inhibition of proliferation. Accordingly, we investigated the role of both Smad-dependent and Smadindependent signaling pathways in TGFb1-TbRIII-induced growth inhibition. TGFb1 has been demonstrated to signal through several Smad-independent signaling pathways, including the MAPK and PI3K/Akt pathways (8,9,11,13,14) . We therefore examined the effect Fig. 2 . TbRIII increases Smad3 activation in TGFb1-stimulated L6 myoblasts. (A) Subconfluent cells were treated with TGFb1 (100 pM) for indicated times and lysed. Phosphorylation of Smad2 and Smad3 was analyzed by western blotting with phospho-specific Smad2 and Smad3 antibodies and total Smad2 and Smad3 levels determined by Smad2 and Smad3 antibodies. (B and C) Subconfluent cells were plated on coverslips and grown in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. After 24 h, cells were treated with TGFb1 (100 pM) for 40 min, fixed with 4% paraformaldehyde and labeled with anti-Smad2 (B, green) or anti-Smad3 (C, red) antibodies. Fluorescence-labeled proteins were visualized by fluorescence microscopy. (D) Subconfluent cells were exposed to TGFb1 (100 pM) for 40 min and lysed. Nuclear fraction (Nu) and cytosolic fraction (Cy) were prepared as described in Materials and Methods and localization of Smads was analyzed by western blotting. Quantification of band intensity in each fraction was carried out using Quantity One software (Bio-Rad) and expressed as the relative ratio (%) in each set (E). The results shown are representative of at least three independent experiments. Statistical significance of differences was assessed using unpaired Student's t-tests ( Ã P , 0.05).
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of PD98059, a mitogen-activated protein kinase kinase inhibitor; SB203580, a p38 kinase inhibitor; SP600125, a c-Jun N-terminal kinase inhibitor; LY294002, a PI3K inhibitor as well as SB431542 (38,39), a TbRI inhibitor on TGFb1-TbRIII-mediated inhibition of proliferation ( Figure 4 ). While PD98059 and LY294002 slightly enhanced TGFb1-mediated inhibition of thymidine incorporation to $80% ( Figure 4A and B) and SP600125 had no significant effect ( Figure 4C ), SB20358 significantly abrogated the effect of TbRIII such that only 30% inhibition of proliferation was observed in the L6-TbRIII cell line ( Figure 4D ). In addition, SB431542 also abrogated the effect of TbRIII, but to a lesser extent, with $40% inhibition of proliferation observed in the L6-TbRIII cell line ( Figure 4E ). We also examined the effects of these inhibitors on TbRIII/TGFb2-mediated growth inhibition. While PD98059 and SP600125 had no significant effect, SB203580 and SB431542 also abrogated TbRIII/ TGFb2-mediated growth inhibition ( Figure 4F ), suggesting a role for both the p38 and TbRI pathways in TbRIII-mediated growth inhibition in response to TGFb1 and TGFb2. The p38 and TbRI inhibitors used have the potential to inhibit other kinases, including the potential for the p38 inhibitor to inhibit TbRI and vice versa (38, 39) . In addition, p38 kinase has been reported to mediate TGFb1-induced apoptosis independently of Smads (11) and to phosphorylate Smads2/3 in their linker region (10) . Therefore, to assess the specificity of the inhibitors used and whether there is any crosstalk between p38 kinase and Smad-dependent signaling pathways in TGFb1-TbRIII-mediated inhibition of proliferation, we examined the effect of SB431542 in TGF-b1-induced p38 kinase activation and the effect of SB203580 on TGFb1-induced Smad phosphorylation. SB431542 did not affect TGFb1-mediated p38 kinase phosphorylation in L6-TbRIII cells ( Figure 5A ). In addition, SB203580 did not inhibit Smad2 or Smad3 phosphorylation in the L6-Neo, L6-TbRIII or L6-TbRIII-Cyto cell lines, whereas SB431542 effectively inhibited but did not abrogate Smad2 and Smad3 phosphorylation in these cell lines ( Figure 5B ). These results demonstrate that, at the doses used, the SB203580 and SB431542 were specific for their respective pathways. Whether there was any crosstalk between p38 kinase and Smad-dependent pathways in L6 myoblasts was further confirmed by investigating the effect of wild-type (p38a-WT) or dominant-negative mutant (p38a-AF) of p38a on TGFb1-or TGFb2-TbRIII-mediated gene induction in L6-TbRIII cells. Expression of either p38a-WT or p38a-AF did not alter TGFb-induced 3TP induction ( Figure 5C ), suggesting that p38 kinase does not significantly crosstalk with TGFb-induced Smad-dependent transcriptional activation in this system.
TbRIII increases p38 kinase phosphorylation
As the inhibitor studies suggested that the p38 kinase pathway may have a significant role in TGFb1-TbRIII-mediated inhibition of proliferation, we investigated whether TbRIII expression altered p38 kinase phosphorylation and whether the cytoplasmic domain of TbRIII contributed to p38 kinase activation. In L6-Neo cells, TGFb1 phosphorylated p38 kinase in a time-dependent fashion from 0.5 to 2 h ( Figure 6A ), and this activation was increased in L6-TbRIII cells. TGFb1 also induced p38 kinase phosphorylation in L6-TbRIII-Cyto cells; however, this activation was always less robust than in L6-TbRIII cells, suggesting a role for the TbRIII cytoplasmic domain in TGFb1-mediated p38 kinase activation. Taken together, these data provide support for a role for p38 kinase in mediating at least a portion of TbRIII/TGFb1-mediated inhibition of proliferation.
p38 kinase and TbRI-mediated signaling mediate TGFb1-induced growth inhibition The present results suggested a role for both a p38/Smad-independent pathway and the TbRI/Smad3-dependent pathway in TGFb1-TbRIIImediated enhanced growth inhibition. To determine whether both pathways were involved, we investigated the effect of p38 kinase and TbRI inhibition on TGFb1-TbRIII-mediated growth inhibition. When cells were exposed to either SB203580 or SB431542 at submaximal concentrations (2 and 0.2 lM, respectively), TGFb1-mediated growth inhibition was only partially inhibited in L6-TbRIII cells ( Figure 6B, left) . In contrast, exposure to SB203580 and SB431542 together completely abrogated TGFb1-mediated growth inhibition in L6-TbRIII cells ( Figure 6B, left) . These data suggest that the p38 kinase and TbRI-mediated Smad3-dependent signaling pathways work in concert in TbRIII-mediated growth inhibition.
TbRIII/TGFb1-induced inhibition of proliferation and growth arrest in human keratinocytes, mammary epithelial cells and ovarian surface epithelial cells To investigate the relevance and broader significance of TbRIII in TGFb1-induced growth inhibition, we initially tested several normal Fig. 3 . TbRIII enhances Smad-dependent promoter activation. Cells were plated on 24-well plate and grown for 24 h in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, after which cells were transfected with pE2.1 (A), p3TP (B), ARE-FAST-1 (C), p3TP with pcDNA3 or pcDNA3-FlagSmad3DE (D) and pRL-SV40 using Fugene 6. After 24 h, cells were exposed to 100 pM TGFb1 for additional 20 h and subjected to dual-luciferase activity measurement. Data are expressed as means ± SDs of at least three independent experiments. Statistical significance of differences was assessed using unpaired Student's t-tests ( Ã P , 0.01).
Mechanism of TbRIII-mediated growth regulation
epithelial cell lines and demonstrated that human keratinocytes (HaCaT cell line) and HMECs were quite sensitive to TGFb1-mediated growth inhibition (up to 90%). In addition, ovarian surface epithelial cells (NOSE007 cell line) were sensitive to TGFb1-mediated growth inhibition (up to 50%). The endogenous expression of TbRIII in those cells was verified by reverse transcription-polymerase chain reaction (data not shown) and binding and cross-linking assays ( Figure 6C ). To provide direct support for TbRIII in contributing to inhibition of proliferation in these cell lines, we used shRNA to TbRIII to knock down TbRIII expression in these cell lines. In HaCaT cells, shRNA to TbRIII decreased TbRIII expression by $80% (Figure 6C, left top) . This decrease in TbRIII expression was accompanied by partial but significant attenuation of TGFb-mediated inhibition of proliferation, suggesting that TbRIII was responsible, at least in part, for mediating the effects of TGFb1 on inhibition of proliferation in HaCaT cells ( Figure 6C, left top) . Similarly, TGFb-induced growth inhibition was partially but consistently attenuated when TbRIII expression was decreased in HMECs ( Figure 6C , left bottom) and in NOSE007 cells ( Figure 6C, right) .
As these results suggested a contribution of TbRIII to TGFbmediated inhibition of proliferation in a broader population of epithelial cell types, we investigated whether the pathways operative in L6 myoblasts were being utilized in these cell types. In HMECs and HaCaT cells, the ALK-5 inhibitor, SB431542 partially inhibited TGFb-mediated inhibition of proliferation ( Figure 6B , right and data not shown). While the p38 kinase inhibitor SB203580 had less potent effects in HMECs and in HaCaT cells, this inhibitor also partially inhibited TGFb-mediated inhibition of proliferation ( Figure 6B , right, 3 H]thymidine was assessed. Growth inhibition was calculated as the ratio of radioactivity with TGFb1 treatment to radioactivity in the absence of TGFb treatment. Data are expressed as means ± SDs of at least three independent experiments. Statistical significance was assessed using unpaired Student's t-tests ( Ã P , 0.005).
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data not shown). In addition, when HMECs were treated with both inhibitors at low doses (0.4 lM of SB431542 and 2 lM of SB203580, respectively), TGFb-mediated growth inhibition was nearly abrogated, suggesting that both pathways were utilized in HMECs to mediate inhibition of proliferation. Taken together, these results support a role for TbRIII in TGFb-mediated growth inhibition, through both p38 kinase and TbRI/Smad3-dependent signaling pathways.
Discussion
The TGFb superfamily co-receptor, TbRIII/betaglycan, was the first TGFb receptor cloned and characterized (40, 41) . However, the molecular domain structure of TbRIII including a short cytoplasmic domain with no clear signaling motifs (40, 41) and reports of TbRIII-independent TGFb signaling (42,43) suggested minor roles for TbRIII including ligand presentation (15) . Although recent studies have suggested essential, non-redundant roles for TbRIII in embryonic development (17, 18) , TGFb signaling (24) and carcinogenesis (19, 20) , how TbRIII mediates its effects remains unclear. We had previously reported an essential role for the cytoplasmic domain of TbRIII in TGFb2-mediated inhibition of proliferation (24) . Here, we establish a role for TbRIII in contributing to TGFb1-and TGFb2-mediated inhibition of proliferation, broadening the significance of TbRIII's role and raising important questions about TbRIII's function apart from ligand presentation. A presentation-independent role for TbRIII in TGFb-mediated inhibition of proliferation is supported by (i) a contribution by the TbRIII cytoplasmic domain, which is dispensable for ligand presentation [(24), Figure 1A ], (ii) the ability of TbRIII to enhance both TGFb1-and TGFb2-mediated inhibition of proliferation to a similar extent, even though TGFb1 is not as dependent on TbRIII for presentation [(24), Figure 1B ] and (iii) the ability of TbRIII to increase the maximum inhibition of proliferation without shifting the dose-response curve for TGFb1 ( Figure 1C and  D) . Instead, through examination of both Smad-dependent and Smadindependent signaling pathways, we present evidence supporting a role for Smad3, TbRI and the p38 MAPK pathway in mediating TbRIII's effects. A role for Smad-dependent signaling in mediating some of TbRIII's effects is supported by (i) TbRIII-enhanced Smad3 (but not Smad2) phosphorylation and nuclear accumulation ( Figure 2 ) and (ii) TbRIII-enhanced Smad3-dependent reporter gene transcription (Figure 3 ) and the ability of dominant-negative Smad3 and the TbRI inhibitor SB431542 to markedly abrogate the effects of TbRIII (Figures 3C and 4E ). This current report adds to a growing body of literature distinguishing the functions and role of TGFb signaling through Smad2 and Smad3. For example, Piek et al. (44) demonstrated different contributions of Smad2 and Smad3 in TGFb1-mediated signaling, with TGFb1-mediated induction of matrix Mechanism of TbRIII-mediated growth regulation metalloproteinase-2 selectively dependent on Smad2 and TGFb1-mediated induction of c-fos, Smad7 and TGFb1 selectively dependent on Smad3. More recently, Kim et al. (45) reported a specific role for Smad3 in mediating the cytostatic effects of TGFb as RNAi-mediated knockdown of Smad3 abrogated TGFb-mediated inhibition of proliferation, whereas RNAi-mediated knockdown of Smad2 enhanced TGFb-mediated inhibition of proliferation. As TbRIII is ubiquitously expressed, the current studies suggest that TbRIII may selectively activate Smad3, with Smad3 having specific functions in regulating TGFb-mediated inhibition of proliferation. Establishing the mechanism of Smad3-specific activation and the identification of TbRIII target genes are active areas of the current investigation. A role for Smad-independent signaling in partly mediating TbRIII's effects is supported by TbRIII-enhanced p38 phosphorylation ( Figure 6A) , and the ability of the p38 inhibitor to markedly abrogate the effects of TbRIII ( Figure 4D and F) . How does TbRIII mediate signaling to the p38 MAPK pathway? Crosstalk between the Smad pathways and MAPK pathways does not appear to be involved, as the TbRI inhibitor had no effect on TGFb1-induced p38 phosphorylation ( Figure 5A ), and expression of either p38a or p38a-AF did not affect TGFb1-and TGFb2-mediated 3TP induction ( Figure 5C ). Instead, the data support a role for the cytoplasmic domain of TbRIII. We have previously demonstrated that TbRIII is phosphorylated by active TbRII on its cytoplasmic domain (24) . Although the full consequences of this phosphorylation remain to be elucidated, one consequence is the recruitment of b-arrestin2 and the subsequent down-regulation of TbRIII and TbRII expression and of TGFb signaling (23) . In addition, b-arrestin2 has been reported to scaffold interacting receptors to signaling pathways including MAPK pathways (46) . Also, we have established that TbRIII interacts with the scaffolding protein GIPC (22) , which stabilizes TbRIII on the cell surface and increases TGFb signaling. The interaction of GIPC with TbRIII could potentially scaffold TbRIII to signaling pathways. Whether b-arrestin2 or GIPC has a role in TGFb-TbRIII-mediated signaling to the p38 MAPK pathway is being investigated.
Crosstalk between signaling pathways is quite common and the TGFb-signaling pathway is no exception. The p38 kinase has been reported to phosphorylate the linker region of Smad3, and this is important for the full transactivation potential of Smad3 (10) . In the present studies, the p38 inhibitor, SB203580, had no effect on Smad2 or Smad3 phosphorylation at the C-terminus (Figure 5B ), suggesting that although p38 kinase might be involved in TGFb1-induced Smad3 activation, it does not crosstalk during TGFb1-TbRIII-mediated growth inhibition. Smad3 can also be regulated by the PI3K/Akt pathway (8, 9) . However, in the present studies, the PI3K inhibitor, LY294002, as well as the mitogen-activated protein kinase kinase inhibitor, PD98059, did not abrograte the effects of TbRIII on TGFb1-mediated growth inhibition ( Figure 4A and B) . Instead, each slightly enhanced TGFb1-mediated growth inhibition, suggesting that TGFb1-TbRIII-mediated activation of Smad3 and subsequent growth inhibition is not mediated through PI3K or ERK, but that these pathways may contribute in other ways to enhance TGFb1-mediated growth inhibition. The kinase inhibitor studies suggest contributions of both TbRI and p38 in TGFb1-and TGFb2-mediated growth inhibition in L6 myoblasts and in HMECs. As TGFb through TbRIII can stimulate Smad3 through both TbRI and p38, which appear to be necessary for the maximum effects of TbRIII on inhibition of proliferation, we are currently investigating how these two pathways crosstalk/integrate to mediate these effects on inhibition of proliferation.
Although the TGFb-signaling pathway has defined roles in human carcinogenesis, initially as a tumor suppressor and then as a tumor promoter (4) , only recently have studies demonstrated a role for TbRIII in the pathogenesis of human cancers. We and others have reported that loss of TbRIII expression through epigenetic silencing, loss of heterozygosity and transcriptional regulation occurs early in breast (19) , kidney (47) , ovarian (21) and prostate cancer (20) , with loss correlating with disease progression. Functional studies in cancer cell lines and murine cancer models have defined a role for TbRIII in negatively regulating motility, invasion and tumor-associated angiogenesis (19, 20) . The current studies in non-transformed cells suggest another potential role for loss of TbRIII expression, namely release from TGFb-mediated inhibition of proliferation early in cancer formation. Interestingly, although most cancers become resistant to TGFb-mediated inhibition of proliferation, known defects in the pathway (i.e. in Smad2/3/4 and TbRII/TbRI) provide the mechanism for only a fraction of these cases. As TbRIII expression is frequently decreased or lost in human cancers (i.e. 65% of breast cancers and 60% of prostate cancers) and here we define decreased TbRIII expression as a mechanism for functional resistance to TGFb-mediated inhibition of proliferation, decreased TbRIII expression could be one of the most common mechanisms for TGFb resistance in human cancers. The role of TbRIII in regulating inhibition of proliferation in these and other cancers is being investigated. 
